Chuan Lin, chairman of TTY Biopharm, one of Taiwan’s leading domestic biomedical players, highlights his ambition to lead the local success story onto the global stage. Chuan goes on to share the company’s transition strategy to leverage their innovative development platforms and manufacturing capabilities to be a partner of choice to the industry and patients worldwide.
The rationale behind targeting East Asia and Central-South America first is that they are emerging markets which have mostly been ignored by big pharma
